Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma Meeting Abstract


Authors: Berdeja, J. G.; Oki, Y.; Patel, M. R.; Copeland, A.; Flinn, I.; Neelapu, S. S.; Viner, J.; Wang, J.; Gerecitano, J. F.; Younes, A.
Abstract Title: Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901849
PROVIDER: wos
Notes: Meeting Abstract: 8537 -- Source: Wos
MSK Authors
  1. Anas Younes
    195 Younes